Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abiraterone + SHR3162
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Abiraterone is an orally active small molecule androgen biosynthesis inhibitor used primarily in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It works by selectively and irreversibly inhibiting the enzyme CYP17A1 (17 alpha-hydroxylase/C17,20-lyase), which is essential for androgen production in the testes, adrenal glands, and tumor tissue. By blocking this enzyme, abiraterone reduces testosterone and other androgen levels that stimulate prostate cancer cell growth[1][4][6]. SHR3162 is a novel agent under investigation; it has been studied in combination with other drugs such as apatinib mesylate or as monotherapy for mCRPC[3]. The combination of abiraterone with SHR3162 is being evaluated for its potential to improve outcomes in patients with metastatic castration-resistant prostate cancer who have previously received treatments like docetaxel[8].
- Brand names
- Zytiga
- Other names
- abiraterone acetate
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)
Beyond the preview
Go deeper on abiraterone + SHR3162.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abiraterone + SHR3162.